BIOLOG-ID
31.8.2021 11:53:07 CEST | Business Wire | Press release
After a public consultation, biolog-id, a global service provider of connected healthcare solutions, through its local partner ATC, has been awarded by the Ministry of Health to deploy Biolog Transfusion Solution in Kuwait Central Blood Bank (KCBB), the national blood bank operator.
Over the years, KCBB has reached a very high scientific level and has acquired a well-deserved reputation for the quality of its blood supply chain. In the Middle East region, this institution is recognized as a leading institution for the quality of its blood supply processes and as an early adopter of leading-edge innovation. On the international stage, the KCBB has also been a pioneer in the AABB (American Association of Blood Banks) accreditation and is for long a member and significant contributor to the ISBT’s (International Society of Blood Transfusion) recommendations.
While the COVID-19 pandemic has challenged the transfusion supply chain, KCBB has chosen to adopt the cutting-edge technology Biolog Transfusion Solution to better drive its operations. Based on RFID, this modular solution combines tags, equipment, and software to offer accurate visibility on blood products throughout the transfusion chain. Designed for healthcare professionals, the solution will support KCBB to enhance GMPs and safety for all processed blood units (Red Blood Cells, Platelets & Plasma).
“We are very honored that KCBB relies on our technology to optimize its processes and its blood distribution tracking”, states Philippe Jacquet, Executive Director of Sales EMEA/LATAM at biolog-id. “This major achievement has been facilitated by our partner in Kuwait, Advanced Technology Company (ATC), who has been instrumental in the management of this project and who will coordinate the implementation of our solution”.
“ATC is very pleased and honored to have been awarded for this project, which will be the first implementation of the state-of-the-art Biolog Transfusion Solution at the prestigious Kuwait Central Blood Bank and its branches. This implementation will definitively be a millstone in the midst of continuous improvement of blood supply safety and blood processing in Kuwait” said M. Mahmoud Chehime, Director – Specialty Diagnostics & LS at ATC.
Biolog Transfusion Solution will be deployed in the Kuwait Central Blood Bank as well as three distant Blood Banks. This implementation will strengthen biolog-id’s presence in the Middle East region, already installed in Egypt and Saudi Arabia.
About biolog-id
:
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and Xerys Invest. Xerys Invest is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies.
Company URL: www.biolog-id.com
About Kuwait Central Blood Bank:
The Kuwait Central Blood Bank’s (KCBB) mission is meeting the country’s needs of the patients for safe, high quality and provision of all transfusion services under the supervision of the government. Provision of educational materials and introduction of awareness of the importance of the blood donation to the public.
KCBB URL: www.kuwaitcentralbloodbank.wordpress.com
About Advanced Technology Company:
ATC is a medical equipment supplier to the Kuwait healthcare sector since 1981. Over time, the Company has become the leading distributor and marketer of state-of-the-art healthcare and environmental products and services.
ATC URL: www.atc.com.kw
View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005479/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Slate Asset Management and OneIM Agree to Acquire Portfolio of Grocery-Anchored Essential Real Estate in the Greater Oslo Region Valued at Approximately €250 Million5.10.2026 08:30:00 CEST | Press release
Slate Asset Management ("Slate"), a global investor and manager focused on essential real estate and infrastructure assets, and One Investment Management (“OneIM”), a global alternative investment manager, today announced they have agreed to acquire a portfolio of eight grocery-anchored retail parks in Norway from Tellus Eiendom AS. The portfolio is located in the Greater Oslo region and is anchored by Norway's leading grocery operators and discount retailers. “We are pleased to be expanding our European Essential real estate platform with this significant acquisition,” said Brady Welch, Co-Founding Partner of Slate Asset Management. “These eight retail parks sit in dominant locations along major transport corridors around Oslo. The portfolio is anchored by Norway's strongest grocery operators and benefits from CPI-linked lease structures, designed to provide durable, inflation-protected cash flows. We look forward to applying our active management to unlock the portfolio’s full potent
Bial Showcases Parkinson’s Research at MDS 20265.10.2026 08:00:00 CEST | Press release
New data provide insights into the experiences and perceptions of people living with Parkinson’s and treatment outcomes Three posters and one oral presentation focus on the discontinued investigational compound BIA 28-6156 [INTENDED FOR MEDICAL AND TRADE MEDIA ONLY] Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, is presenting 16 scientific posters at the International Congress of Parkinson’s Disease and Movement Disorders (MDS 2026), taking place in Seoul, Korea, from 4 to 8 October. Reflecting Bial’s commitment to listening to and learning directly from people living with Parkinson’s, two presentations cover research initiatives focused on understanding their experiences, perspectives, and priorities. The first is the Patient Endpoint Preference Project (PEPP), an ongoing multinational observational study that seeks to identify and prioritise the symptoms and outcomes that matter most to people living with Parkinson’s. The second is th
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 16:50:00 CEST | Press release
Survival estimate remained at 48% between years two and three, extending evidence of durable benefitResults observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines of therapy; nearly three-quarters of patients had platinum-resistant or refractory cancer Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from
Andersen Global udvider sin juridiske virksomhed i Pakistan med et nyt medlemsfirma2.10.2026 22:36:00 CEST | Pressemeddelelse
Andersen Global styrker sin juridiske tilstedeværelse i Pakistan, idet Samdani & Qureshi, der har været samarbejdspartner siden 2021, skifter navn til Andersen Legal in Pakistan og bliver den seneste medlemsvirksomhed, der slutter sig til organisationen. Andersen Legal in Pakistan har hovedkontor i Islamabad og rådgiver både indenlandske og internationale klienter, herunder virksomheder, investorer, finansielle institutioner, offentlige enheder, udviklingsorganisationer og privatpersoner, om juridiske, kommercielle og regulatoriske forhold. Firmaet arbejder også med voldgift og tvistbilæggelse og rådgiver om komplekse transaktioner, investeringer, finansiering, projekter og tvister i Pakistan og på tværs af landegrænser. "Vores tilgang bygger på stærkt engagement fra ledelsen, klar kommunikation og disciplineret analyse med fokus på at levere rådgivning, som vores klienter kan omsætte til handling," sagde Nudrat Ejaz Piracha, partner hos Andersen Legal in Pakistan. "Ved at blive en del
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 17:12:00 CEST | Press release
Appointments expand emnify executive team to accelerate global growth emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom